Brief: Neurosense Reports New Data on Clinical Efficacy In Phase 2b ALS Trial

Neurosense Therapeutics

14/12/2023 14:29

Dec 14 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE REPORTS NEW DATA: STATISTICALLY SIGNIFICANT
CLINICAL
EFFICACY IN PHASE 2B ALS TRIAL
    * NEUROSENSE THERAPEUTICS LTD - PRIMARY BIOMARKER ENDPOINTS,
TDP-43 AND PROSTAGLADIN2, ARE EXPECTED IN H1 2024
    * NEUROSENSE THERAPEUTICS LTD - A STATISTICALLY SIGNIFICANT,
37.4%
DIFFERENCE (P=0.03), SLOWING OF DISEASE PROGRESSION IN ALSFRS-R
    * NEUROSENSE THERAPEUTICS LTD - NEUROFILAMENT BIOMARKER
RESULTS
FROM BIOGEN COLLABORATION EXPECTED IN JANUARY 2024
    * NEUROSENSE THERAPEUTICS LTD - PRIMEC'S MEANINGFUL EFFECT
MAGNITUDE, STRONG SAFETY PROFILE, AND UNIQUE MECHANISM OF ACTION
WILL BE DISCUSSED WITH FDA

Source text for Eikon:  ID:nPn90YKPma 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))